½ÃÀ庸°í¼­
»óǰÄÚµå
1402081

¼¼°èÀÇ °ú¹Î¼ºÆó·Å ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2023-2030³â)

Global Hypersensitivity Pneumonitis Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 179 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

°ú¹Î¼ºÆó·Å ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â Á¶»ç ±â°£ÀÎ 2023-2030³â CAGRÀÌ 5.26%·Î, 2022³â 9¾ï 5,650¸¸ ´Þ·¯¿¡¼­ 2030³â±îÁö´Â ¾à 14¾ï 4,142¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

°ú¹Î¼ºÆó·Å(HP) ¶Ç´Â ¿ÜÀμº ¾Ë·¹¸£±â¼º ÆóÆ÷¿°Àº ´Ù¾çÇÑ À¯±â ¹°ÁúÀ̳ª ¾Ë·¹¸£°Õ¿¡ ¹Ýº¹ÀûÀ¸·Î ³ëÃâµÇ¾î ¹ß»ýÇÏ´Â Èñ±ÍÇÑ Æó ÁúȯÀÔ´Ï´Ù. ¹Î°¨ÇÑ »ç¶÷ÀÌ ÀÌ·¯ÇÑ ¹°ÁúÀ» ÈíÀÔÇÏ¸é ¸é¿ª ü°è°¡ °úµµÇÑ ¸é¿ª ¹ÝÀÀÀ» ÀÏÀ¸ÄÑ Æó¿¡ ¿°ÁõÀ» ÀÏÀ¸Åµ´Ï´Ù.

½ÃÀå ¿ªÇÐ

ÀÎ½Ä Á¦°í¿Í Áø´Ü ´É·ÂÀÇ Çâ»óÀ¸·Î °ú¹Î¼ºÆó·ÅÀÇ »ç·Ê ½Äº°°ú º¸°í°¡ ¿ëÀÌÇØÁö¸é¼­ Áø´Ü °Ë»ç ¹× °ü¸® Àü·«¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °õÆÎÀÌ, Á¶·ù ¹è¼³¹°°ú °°Àº ȯ°æÀû ¿äÀΰú ÇÔ²² ³ó¾÷ ¹× ¸ñ°ø°ú °°Àº »ê¾÷¿¡¼­ÀÇ Á÷¾÷Àû ³ëÃâÀÌ ÀÌ ÁúȯÀÇ À¯Çà¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¿µ»ó Áø´Ü ±â¼ú ¹× Æó ±â´É °Ë»ç µî Áø´Ü ±â¼úÀÇ ¹ßÀüÀº °ú¹Î¼ºÆó·ÅÀÇ Á¤È®ÇÑ Á¶±â Áø´Ü¿¡ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, Áø´Ü Åø¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. °ú¹Î¼ºÆó·ÅÀÇ ¸ÞÄ¿´ÏÁò°ú À§Çè ¿äÀο¡ ´ëÇÑ ¿¬±¸´Â »õ·Î¿î Áø´Ü ¹× Ä¡·á¹ý °³¹ß·Î À̾îÁ® ½ÃÀåÀ» ´õ¿í È®´ë½Ã۰í ÀÖ½À´Ï´Ù. Àü ¼¼°è ÀÇ·áºñ ÁöÃâÀÌ Áõ°¡ÇÔ¿¡ µû¶ó HP °ü¸®¸¦ À§ÇÑ È¯ÀÚ °ü¸® ¹× ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. »ê¾÷¾ÈÀüº¸°Ç ¹× ȯ°æº¸°Ç¿¡ ´ëÇÑ Á¤ºÎÀÇ Á¤Ã¥, ±ÔÁ¦ ¹× Á¤Ã¥ ÁöħÀº °ú¹Î¼ºÆó·Å¿¡ ´ëóÇϱ⠽¬¿î ȯ°æÀ» Á¶¼ºÇÏ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

Á¶»ç ¸®Æ÷Æ®´Â Porter's Five Forces ¸ðµ¨, ½ÃÀåÀÇ ¸Å·Â ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ç°í ÀÖ½À´Ï´Ù. ÀÌ ÅøÀº ¾÷°èÀÇ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇϰí, ¼¼°è ·¹º§¿¡¼­ÀÇ °æÀï ¸Å·ÂÀ» Æò°¡Çϴµ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ÀÌ ÅøÀº ¼¼°èÀÇ °ú¹Î¼ºÆó·Å ½ÃÀåÀÇ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼öµµ ÀÖ½À´Ï´Ù. °ú¹Î¼ºÆó·Å »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº ÀÌ ¿¬±¸¿¡ ÀüüÀûÀÎ ¾îÇÁ·ÎÄ¡¸¦ Á¦°øÇÕ´Ï´Ù.

Áö¿ª ºÐ¼®

º» ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿¡¼­ °ú¹Î¼ºÆó·Å ½ÃÀå ÇöÀç ¹× ÇâÈÄ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ À¯¸íÇÑ Àü Áö¿ª¿¡¼­ °³º° ¿ëµµ ºÎ¹®ÀÇ ¼ö¿ä¡¤ÃßÁ¤¡¤¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.

Ä¿½ºÅÒ ¿ä°ÇÀÌ ÀÖ´Â °æ¿ì ¹®ÀÇÇØÁֽñ⠹ٶø´Ï´Ù. Value Market ResearchÀÇ ¿¬±¸ÆÀÀÌ °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü º¸°í¼­¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀåÀÇ ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ½º³À¼ô

Á¦3Àå °ú¹Î¼ºÆó·Å - »ê¾÷ ºÐ¼®

  • ¼­·Ð : ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • ¾÷°è µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀç·á ºÐ¼®
    • ¿øÀç·á ¸®½ºÆ®
    • ¿øÀç·á Á¦Á¶¾÷ü ¸®½ºÆ®
    • ÁÖ¿ä ¿øÀç·áÀÇ °¡°Ý µ¿Çâ
  • ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
  • ¸¶ÄÉÆÃ Ã¤³Î
    • ´ÙÀÌ·ºÆ® ¸¶ÄÉÆÃ
    • ÀδÙÀÌ·ºÆ® ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå ¼¼°èÀÇ °ú¹Î¼ºÆó·Å ½ÃÀå ºÐ¼® : Æø·Î¿øº°

  • °³¿ä : Æø·Î¿øº°
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • Æø·Î¿øº° ºÐ¼®
  • Á÷¾÷¼º Æø·Î
  • ȯ°æ ¾Ë·¹¸£°Õ
  • ¾àÁ¦¼º Æø·Î
  • ±âŸ

Á¦6Àå ¼¼°èÀÇ °ú¹Î¼ºÆó·Å ½ÃÀå ºÐ¼® : À¯Çüº°

  • °³¿ä : À¯Çüº°
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • À¯Çüº° ºÐ¼®
  • ¸¸¼º °ú¹Î¼ºÆó·Å
  • ±Þ¼º °ú¹Î¼ºÆó·Å

Á¦7Àå ¼¼°èÀÇ °ú¹Î¼ºÆó·Å ½ÃÀå ºÐ¼® : Áø´Üº°

  • °³¿ä : Áø´Üº°
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • Áø´Üº° ºÐ¼®
  • Æó±â´É °Ë»ç
  • ¿µ»ó °Ë»ç
  • »ý°Ë
  • ±âŸ

Á¦8Àå ¼¼°èÀÇ °ú¹Î¼ºÆó·Å ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼­·Ð
  • ºÏ¹Ì ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì : ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • À¯·´ ºÎ¹®º°
    • À¯·´ : ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • µ¿³²¾Æ½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä« ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º°
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå °ú¹Î¼ºÆó·Å ±â¾÷ÀÇ °æÀï ±¸µµ

  • °ú¹Î¼ºÆó·Å ½ÃÀå °æÀï
  • Á¦ÈÞ¡¤Çù·Â¡¤ÇÕÀÇ
  • ÇÕº´¡¤Àμö
  • ½ÅÁ¦Ç° Ãâ½Ã
  • ±âŸ °³¹ß

Á¦10Àå ±â¾÷ °³¿ä

  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • Johnson & Johnson Services Inc.
  • F.Hoffmann-La Roche Ltd.
  • Boehringer Ingelheim International GmbH
  • AstraZeneca Plc.
  • GlaxoSmithKline plc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis International AG
  • Merck KGaA
KSA 24.01.11

The global demand for Hypersensitivity Pneumonitis Market is presumed to reach the market size of nearly USD 1441.42 MN by 2030 from USD 956.5 MN in 2022 with a CAGR of 5.26% under the study period 2023 - 2030.

Hypersensitivity pneumonitis (HP), or extrinsic allergic alveolitis, is a rare lung condition triggered by repeated exposure to various organic substances or allergens. When susceptible individuals inhale these substances, their immune system mounts an exaggerated immune response, causing inflammation in the lungs.

MARKET DYNAMICS

Increased awareness and improved diagnostic capabilities lead to better identification and reporting of hypersensitivity pneumonitis cases, driving demand for diagnostic tests and management strategies. Occupational exposures in industries like agriculture and woodworking, along with environmental factors such as mold or bird droppings, contribute significantly to the condition's prevalence. Advancements in diagnostic technologies, including imaging techniques and pulmonary function tests, play a pivotal role in accurate and early hypersensitivity pneumonitis diagnosis, fostering demand for diagnostic tools. Research initiatives focusing on understanding HP's mechanisms and risk factors lead to novel diagnostic methods and treatments, further expanding the market. Rising healthcare expenditure globally enables improved patient care and access to healthcare services for HP management. Supportive government policies, regulations, and guidelines pertaining to occupational safety and environmental health contribute to creating an environment conducive to addressing hypersensitivity pneumonitis.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of hypersensitivity pneumonitis. The growth and trends of hypersensitivity pneumonitis industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the hypersensitivity pneumonitis market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Source Of Exposure

  • Occupational Exposure
  • Environmental Allergens
  • Drug-Induced Exposure
  • Others

By Type

  • Chronic Hypersensitivity Pneumonitis
  • Acute Hypersensitivity Pneumonitis

By Diagnosis

  • Pulmonary Function Tests
  • Imaging Tests
  • Biopsy
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Hypersensitivity Pneumonitis market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Hypersensitivity Pneumonitis market include Johnson & Johnson Services Inc., F.Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH, AstraZeneca Plc., GlaxoSmithKline plc., Pfizer Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Novartis International AG, Merck KGaA, and others. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . HYPERSENSITIVITY PNEUMONITIS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Source of Exposure
    • 3.7.2 Market Attractiveness Analysis By Type
    • 3.7.3 Market Attractiveness Analysis By Diagnosis
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL HYPERSENSITIVITY PNEUMONITIS MARKET ANALYSIS BY SOURCE OF EXPOSURE

  • 5.1 Overview by Source of Exposure
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Source of Exposure
  • 5.4 Occupational Exposure Historic and Forecast Sales by Regions
  • 5.5 Environmental Allergens Historic and Forecast Sales by Regions
  • 5.6 Drug-Induced Exposure Historic and Forecast Sales by Regions
  • 5.7 Others Historic and Forecast Sales by Regions

6 . GLOBAL HYPERSENSITIVITY PNEUMONITIS MARKET ANALYSIS BY TYPE

  • 6.1 Overview by Type
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Type
  • 6.4 Chronic Hypersensitivity Pneumonitis Historic and Forecast Sales by Regions
  • 6.5 Acute Hypersensitivity Pneumonitis Historic and Forecast Sales by Regions

7 . GLOBAL HYPERSENSITIVITY PNEUMONITIS MARKET ANALYSIS BY DIAGNOSIS

  • 7.1 Overview by Diagnosis
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Diagnosis
  • 7.4 Pulmonary Function Tests Historic and Forecast Sales by Regions
  • 7.5 Imaging Tests Historic and Forecast Sales by Regions
  • 7.6 Biopsy Historic and Forecast Sales by Regions
  • 7.7 Others Historic and Forecast Sales by Regions

8 . GLOBAL HYPERSENSITIVITY PNEUMONITIS MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2. North America By Segment Sales Analysis
    • 8.3.3. North America By Country Sales Analysis
    • 8.3.4. United State Sales Analysis
    • 8.3.5. Canada Sales Analysis
    • 8.3.6. Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2. Europe by Segment Sales Analysis
    • 8.4.3. Europe by Country Sales Analysis
    • 8.4.4. United Kingdom Sales Analysis
    • 8.4.5. France Sales Analysis
    • 8.4.6. Germany Sales Analysis
    • 8.4.7. Italy Sales Analysis
    • 8.4.8. Russia Sales Analysis
    • 8.4.9. Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2. Asia Pacific by Segment Sales Analysis
    • 8.5.3. Asia Pacific by Country Sales Analysis
    • 8.5.4. China Sales Analysis
    • 8.5.5. India Sales Analysis
    • 8.5.6. Japan Sales Analysis
    • 8.5.7. South Korea Sales Analysis
    • 8.5.8. Australia Sales Analysis
    • 8.5.9. South East Asia Sales Analysis
    • 8.5.10. Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2. Latin America by Segment Sales Analysis
    • 8.6.3. Latin America by Country Sales Analysis
    • 8.6.4. Brazil Sales Analysis
    • 8.6.5. Argentina Sales Analysis
    • 8.6.6. Peru Sales Analysis
    • 8.6.7. Chile Sales Analysis
    • 8.6.8. Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2. Middle East & Africa by Segment Sales Analysis
    • 8.7.3. Middle East & Africa by Country Sales Analysis
    • 8.7.4. Saudi Arabia Sales Analysis
    • 8.7.5. UAE Sales Analysis
    • 8.7.6. Israel Sales Analysis
    • 8.7.7. South Africa Sales Analysis
    • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE HYPERSENSITIVITY PNEUMONITIS COMPANIES

  • 9.1. Hypersensitivity Pneumonitis Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10 . COMPANY PROFILES OF HYPERSENSITIVITY PNEUMONITIS INDUSTRY

  • 10.1. Company Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Johnson & Johnson Services Inc.
    • 10.3.1. Company Overview
    • 10.3.2. Company Revenue
    • 10.3.3. Products
    • 10.3.4. Recent Developments
  • 10.4. F.Hoffmann-La Roche Ltd.
    • 10.4.1. Company Overview
    • 10.4.2. Company Revenue
    • 10.4.3. Products
    • 10.4.4. Recent Developments
  • 10.5. Boehringer Ingelheim International GmbH
    • 10.5.1. Company Overview
    • 10.5.2. Company Revenue
    • 10.5.3. Products
    • 10.5.4. Recent Developments
  • 10.6. AstraZeneca Plc.
    • 10.6.1. Company Overview
    • 10.6.2. Company Revenue
    • 10.6.3. Products
    • 10.6.4. Recent Developments
  • 10.7. GlaxoSmithKline plc.
    • 10.7.1. Company Overview
    • 10.7.2. Company Revenue
    • 10.7.3. Products
    • 10.7.4. Recent Developments
  • 10.8. Pfizer Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Company Revenue
    • 10.8.3. Products
    • 10.8.4. Recent Developments
  • 10.9. Sanofi S.A.
    • 10.9.1. Company Overview
    • 10.9.2. Company Revenue
    • 10.9.3. Products
    • 10.9.4. Recent Developments
  • 10.10. Teva Pharmaceutical Industries Ltd.
    • 10.10.1. Company Overview
    • 10.10.2. Company Revenue
    • 10.10.3. Products
    • 10.10.4. Recent Developments
  • 10.11. Novartis International AG
    • 10.11.1. Company Overview
    • 10.11.2. Company Revenue
    • 10.11.3. Products
    • 10.11.4. Recent Developments
  • 10.12. Merck KGaA
    • 10.12.1. Company Overview
    • 10.12.2. Company Revenue
    • 10.12.3. Products
    • 10.12.4. Recent Developments
  • 10.13. Others
    • 10.13.1. Company Overview
    • 10.13.2. Company Revenue
    • 10.13.3. Products
    • 10.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦